Literature DB >> 12409992

A potential antidepressant activity of SA4503, a selective sigma 1 receptor agonist.

G Skuza1, Z Rogóz.   

Abstract

The aim of the present study was to examine SA4503 [1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride], a novel selective receptor agonist, in respect of its potential antidepressant action. To this end we used a forced swimming test in rats to study SA4503 alone, as well as its interaction with imipramine, a classic tricyclic antidepressant. SA4503 decreased the immobility time in the forced swimming test in rats (although only at one of the three doses used); at the same time it did not change the locomotor activity recorded under the same experimental conditions. Moreover, SA4503 showed a synergistic effect with imipramine in the forced swimming test (both those compounds given jointly decreased the immobility time, but were ineffective when administered separately). It had previously been shown that repeated administration of antidepressants with different pharmacological profiles enhanced the action of D-amphetamine, quinpirole and other dopamine stimulants. SA4503 administered repeatedly increased the locomotor hyperactivity induced by D-amphetamine and quinpirole (a dopamine D /D receptor agonist), but not by (+/-)-7-hydroxy-dipropyloamino-tetralin hydrobromide [(+/-)-7-OH-DPAT; a dopamine D receptor agonist]. The results presented in this paper support the suggestion that SA4503 may have potential antidepressive properties.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12409992     DOI: 10.1097/00008877-200211000-00003

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  13 in total

1.  The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine.

Authors:  Kelli R Rodvelt; Clark E Oelrichs; Lucas R Blount; Kuo-Hsien Fan; Susan Z Lever; John R Lever; Dennis K Miller
Journal:  Drug Alcohol Depend       Date:  2011-02-01       Impact factor: 4.492

Review 2.  Sigma receptors: potential targets for a new class of antidepressant drug.

Authors:  James A Fishback; Matthew J Robson; Yan-Tong Xu; Rae R Matsumoto
Journal:  Pharmacol Ther       Date:  2010-05-11       Impact factor: 12.310

3.  Novel sigma (sigma) receptor agonists produce antidepressant-like effects in mice.

Authors:  Jiajia Wang; Aisha L Mack; Andrew Coop; Rae R Matsumoto
Journal:  Eur Neuropsychopharmacol       Date:  2007-03-21       Impact factor: 4.600

Review 4.  Sigma-1 receptor chaperones in neurodegenerative and psychiatric disorders.

Authors:  Shang-Yi A Tsai; Michael J Pokrass; Neal R Klauer; Nicole E De Credico; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2014-10-21       Impact factor: 6.902

Review 5.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

6.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

7.  SA 4503 attenuates cocaine-induced hyperactivity and enhances methamphetamine substitution for a cocaine discriminative stimulus.

Authors:  Kelli R Rodvelt; Susan Z Lever; John R Lever; Lucas R Blount; Kuo-Hsien Fan; Dennis K Miller
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

Review 8.  The pharmacology of sigma-1 receptors.

Authors:  Tangui Maurice; Tsung-Ping Su
Journal:  Pharmacol Ther       Date:  2009-07-18       Impact factor: 12.310

Review 9.  Multi-Target Directed Ligands (MTDLs) Binding the σ1 Receptor as Promising Therapeutics: State of the Art and Perspectives.

Authors:  Francesca Serena Abatematteo; Mauro Niso; Marialessandra Contino; Marcello Leopoldo; Carmen Abate
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

10.  Pharmacology and therapeutic potential of sigma(1) receptor ligands.

Authors:  E J Cobos; J M Entrena; F R Nieto; C M Cendán; E Del Pozo
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.